Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellectis (CLLS) Current Deferred Revenue (2016 - 2025)

Cellectis has reported Current Deferred Revenue over the past 6 years, most recently at $96.8 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $96.8 million for Q4 2025, down 13.69% from a year ago — trailing twelve months through Dec 2025 was $96.8 million (down 13.69% YoY), and the annual figure for FY2025 was $96.8 million, down 13.69%.
  • Current Deferred Revenue for Q4 2025 was $96.8 million at Cellectis, down from $112.2 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for CLLS hit a ceiling of $112.2 million in Q4 2024 and a floor of $59000.0 in Q4 2022.
  • Median Current Deferred Revenue over the past 4 years was $103.6 million (2023), compared with a mean of $79.8 million.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 186891.53% in 2023 and later fell 13.69% in 2025.
  • Cellectis' Current Deferred Revenue stood at $59000.0 in 2022, then skyrocketed by 186891.53% to $110.3 million in 2023, then rose by 1.66% to $112.2 million in 2024, then dropped by 13.69% to $96.8 million in 2025.
  • The last three reported values for Current Deferred Revenue were $96.8 million (Q4 2025), $112.2 million (Q4 2024), and $110.3 million (Q4 2023) per Business Quant data.